I just saw this abstract in The Lancet:
"Alemtuzumab reduced disease activity compared with interferon beta-1a in most of the analysed subgroups. Significantly greater numbers of patients experienced sustained improvement in disability after treatment with alemtuzumab than interferon beta-1a. The efficacy offered by alemtuzumab is a substantial advance in the treatment of multiple sclerosis."
http://www.thelancet.com/journals/la...020-5/abstract
Wow! I'll have to ask my neuro about this stuff. But no idea how it compares to Ty...
Todd
"Alemtuzumab reduced disease activity compared with interferon beta-1a in most of the analysed subgroups. Significantly greater numbers of patients experienced sustained improvement in disability after treatment with alemtuzumab than interferon beta-1a. The efficacy offered by alemtuzumab is a substantial advance in the treatment of multiple sclerosis."
http://www.thelancet.com/journals/la...020-5/abstract
Wow! I'll have to ask my neuro about this stuff. But no idea how it compares to Ty...
Todd
Comment